MedPath

Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Completed
Conditions
Recurrent Retinoblastoma
Extraocular Retinoblastoma
Intraocular Retinoblastoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Registration Number
NCT00690469
Lead Sponsor
Children's Oncology Group
Brief Summary

This laboratory study is looking at genetic mutations and environmental exposure in young patients with retinoblastoma and in their parents and young healthy unrelated volunteers. Gathering information about gene mutations and environmental exposure may help doctors learn more about the causes of retinoblastoma in young patients.

Detailed Description

OBJECTIVES:

I. To investigate the role of genotypes for carcinogen metabolizing enzymes (CME) and DNA repair proteins(DRPs) of the father of children diagnosed with retinoblastoma (RB) and his environmental exposures prior to the child?s conception in the etiology of sporadic bilateral retinoblastoma.

II. To test if the prevalence of preconception environmental exposures and polymorphisms with known or predicted functional consequences in genes for CMEs and DRPs is different in fathers of children with sporadic bilateral RB compared with fathers of the control group.

III. To test if the prevalence of the father?s preconception environmental exposures and his polymorphisms in CMEs and DRPs differs between subsets of cases defined by the type of mutation at the RB1 gene locus.

IV. To investigate the role of genotypes for CMEs and DRPs of the mother and child and environmental exposures after the child?s conception in the etiology of sporadic unilateral RB.

V. To test if the prevalence of environmental exposures during the pregnancy and polymorphisms with known or predicted functional consequences in CMEs is different in the mothers of children with sporadic unilateral RB compared with mothers of the control group.

VI. To test if the prevalence of polymorphisms in genes for CMEs and DRPs with known or predicted functional consequences is different in the children with sporadic unilateral RB compared with controls.

VII. To test if the prevalence of gestational exposures and polymorphisms in genes for CMEs of the mother and the polymorphisms in genes for CME and DRPs in the children differs between subsets of cases defined by the type of mutation at the RB1 gene locus.

OUTLINE: This is a multicenter study.

Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.

Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.

For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened. Blood samples undergo DNA-based sequencing analysis, single nucleotide polymorphism genotyping, quantitative Southern blot analysis, isolation of RNA and reverse transcriptase-polymerase chain reaction analysis, and loss of heterozygosity analysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
234
Inclusion Criteria
  • Cases must meet the following criteria:

    • Diagnosed with sporadic retinoblastoma (RB) on or after 07/01/2006

      • No familial retinoblastoma
    • Have permission of physician to contact the parents

    • Diagnosed and/or treated at a Children's Oncology Group (COG) institution or *Wills Eye Hospital

  • Controls must meet 1 of the following criteria:

    • Mother of a child with unilateral RB
    • Father of a child with bilateral RB
    • Age-matched non-blood-related child if possible
  • Must reside in the U.S. or Canada

  • Must have telephone in the home

  • Biological parent speaks English or Spanish

  • Concurrent treatment on a therapeutic trial is NOT required

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Observational (biomarker analysis)Laboratory Biomarker AnalysisParticipants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology. Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available. For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened.
Observational (biomarker analysis)Questionnaire AdministrationParticipants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology. Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available. For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened.
Primary Outcome Measures
NameTimeMethod
Probability that mothers of unilateral RB cases are more likely to have specific DNA-repair gene variants than the mothers of the control groupNot Provided
Significant effect of specific DNA repair and CME genotypes on the risk of unilateral RBNot Provided
Association of the probability of having a child with bilateral retinoblastoma (RB) with the paternal genotype for selected DNA repair and carcinogen metabolizing enzymes (CME) genesNot Provided
Probability that the bilateral RB1 mutation subtype will vary by DNA repair or CME genotype or preconception exposures of the fathers of bilateral RB casesNot Provided
Probability that the unilateral RB1 mutation subtype will vary by DNA repair or CME genotype of the mother, of the affected child, and with gestational exposuresNot Provided
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (52)

Children's Healthcare of Atlanta - Egleston

🇺🇸

Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

University of Missouri - Ellis Fischel

🇺🇸

Columbia, Missouri, United States

Rainbow Babies and Childrens Hospital

🇺🇸

Cleveland, Ohio, United States

Children's Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Driscoll Children's Hospital

🇺🇸

Corpus Christi, Texas, United States

Children's Hospital of Pittsburgh of UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

Texas Tech University Health Sciences Center-Amarillo

🇺🇸

Amarillo, Texas, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Nemours Children's Clinic-Jacksonville

🇺🇸

Jacksonville, Florida, United States

Nemours Children's Clinic - Pensacola

🇺🇸

Pensacola, Florida, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

Saint Mary's Hospital

🇺🇸

West Palm Beach, Florida, United States

Spectrum Health at Butterworth Campus

🇺🇸

Grand Rapids, Michigan, United States

San Jorge Children's Hospital

🇵🇷

San Juan, Puerto Rico

MedStar Georgetown University Hospital

🇺🇸

Washington, District of Columbia, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

IWK Health Centre

🇨🇦

Halifax, Nova Scotia, Canada

British Columbia Children's Hospital

🇨🇦

Vancouver, British Columbia, Canada

UCSF Medical Center-Mount Zion

🇺🇸

San Francisco, California, United States

University of Miami Miller School of Medicine-Sylvester Cancer Center

🇺🇸

Miami, Florida, United States

Indiana University/Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Wayne State University/Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

University of Minnesota/Masonic Cancer Center

🇺🇸

Minneapolis, Minnesota, United States

Nevada Cancer Research Foundation CCOP

🇺🇸

Las Vegas, Nevada, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Alfred I duPont Hospital for Children

🇺🇸

Wilmington, Delaware, United States

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

Nemours Children's Clinic - Orlando

🇺🇸

Orlando, Florida, United States

Johns Hopkins All Children's Hospital

🇺🇸

Saint Petersburg, Florida, United States

Sacred Heart Hospital

🇺🇸

Pensacola, Florida, United States

University of Illinois

🇺🇸

Chicago, Illinois, United States

Helen DeVos Children's Hospital at Spectrum Health

🇺🇸

Grand Rapids, Michigan, United States

Dayton Children's Hospital

🇺🇸

Dayton, Ohio, United States

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

Saint Joseph's Hospital/Children's Hospital-Tampa

🇺🇸

Tampa, Florida, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Children's Hospital Central California

🇺🇸

Madera, California, United States

UCSF Medical Center-Parnassus

🇺🇸

San Francisco, California, United States

Lurie Children's Hospital-Chicago

🇺🇸

Chicago, Illinois, United States

University of Iowa/Holden Comprehensive Cancer Center

🇺🇸

Iowa City, Iowa, United States

Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

University of Kentucky/Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

Columbia Regional

🇺🇸

Columbia, Missouri, United States

The Childrens Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Cook Children's Medical Center

🇺🇸

Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath